Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Impax Laboratories Inc    IPXL

News SummaryMost relevantAll newsSector news 

Impax Laboratories Inc : Impax Laboratories to Present at the UBS Global Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
05/20/2013 | 01:35pm CET

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the UBS Global Healthcare Conference on Wednesday, May 22, at 9:00 a.m. Eastern Standard Time. The conference will be held at the Sheraton New York Hotel.

Individuals may listen to the live or an archived presentation made at the conference, which will be posted in the investor relations section of the Company's web site at www.impaxlabs.com. This presentation will be archived on the Company's web site for 30 days.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. (Impax) is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams and ointments. For more information, please visit the Company's Web site at: www.impaxlabs.com.

Impax Laboratories, Inc.
Mark Donohue, 215-558-4526
Investor Relations and Corporate Communications

© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
12/01 IMPAX LABORATORIES INC : Khang & Khang LLP Announces Securities Class Action Law..
12/01 Law Offices of Howard G. Smith Commences Investigation on Behalf of Impax Lab..
12/01 IMPAX LABORATORIES INC. SHAREHOLDER : Former SEC Attorney Willie Briscoe and Po..
12/01 IMPAX LABORATORIES INC : Lundin Law PC Announces Securities Class Action Lawsuit..
12/01 IMPAX ASSET MANAGEMENT : Hikes Dividend As Assets Under Management Surge
11/30 IMPAX ASSET MANAGEMENT : Raises GBP149 Million For Renewable Energy Fund
11/29 IMPAX LABORATORIES INC : Khang & Khang LLP Announces Securities Class Action Law..
11/29 IMPAX LABORATORIES INC : SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC ..
11/29 IMPAX LABORATORIES INC : Kessler Topaz Meltzer & Check, LLP Reminds Impax Labora..
11/28 IMPAX LABORATORIES INC : Change in Directors or Principal Officers, Amendments t..
More news
Sector news : Pharmaceuticals - NEC
12:36a Pharma execs weigh in on possible changes under Trump
12:24aDJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
12/01 GLAXOSMITHKLINE : GSK biotech asthma drug wins UK approval after extra price cut
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
11/11 Healthcare ratings roundup - downgrades
11/10 Impax Quickly Destroys Shareholder Value
11/09 Impax Laboratories (IPXL) Q3 2016 Results - Earnings Call Transcript
11/09 Impax Labs Q3 falls short of consensus; impairment charge and softer guidance..
11/09 Midday Gainers / Losers
Financials ($)
Sales 2016 845 M
EBIT 2016 144 M
Net income 2016 -40,0 M
Debt 2016 562 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017 10,44
EV / Sales 2016 1,87x
EV / Sales 2017 1,51x
Capitalization 1 016 M
More Financials
Duration : Period :
Impax Laboratories Inc Technical Analysis Chart | IPXL | US45256B1017 | 4-Traders
Full-screen chart
Technical analysis trends IMPAX LABORATORIE...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 15
Average target price 19,3 $
Spread / Average Target 40%
Consensus details
EPS Revisions
More Estimates Revisions
George Frederick Wilkinson President, Chief Executive Officer & Director
Robert L. Burr Chairman
Andrew Schaschl Senior Vice President-Global Operations
Bryan M. Reasons Chief Financial Officer & Senior VP-Finance
Vishal K. Gupta CSO, Senior Vice President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON8.43%303 013
PFIZER INC.-2.54%190 910
ROCHE HOLDING LTD.-17.98%189 262
NOVARTIS AG-19.07%177 818
MERCK & CO., INC.15.85%167 524
More Results